Imunovir 500mg Tablets
- Name:
Imunovir 500mg Tablets
- Company:
Kora Healthcare
- Active Ingredients:
- Legal Category:
Product subject to medical prescription which may not be renewed (A)
Patient Information Leaflet Patient Information Leaflet last updated on medicines.ie: 26/06/17
(Click to Download)
Print ViewKeyword Search SPC
1. NAME OF THE MEDICINAL PRODUCT
1. NAME OF THE MEDICINAL PRODUCT
2. QUALITATIVE AND QUANTITATIVE COMPOSITION
2. QUALITATIVE AND QUANTITATIVE COMPOSITION
3. PHARMACEUTICAL FORM
3. PHARMACEUTICAL FORM
4. CLINICAL PARTICULARS
4. CLINICAL PARTICULARS
5. PHARMACOLOGICAL PROPERTIES
5. PHARMACOLOGICAL PROPERTIES
6. PHARMACEUTICAL PARTICULARS
6. PHARMACEUTICAL PARTICULARS
7. MARKETING AUTHORISATION HOLDER
7. MARKETING AUTHORISATION HOLDER
8. MARKETING AUTHORISATION NUMBER(S)
8. MARKETING AUTHORISATION NUMBER(S)
9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION
9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION
10. DATE OF REVISION OF THE TEXT
10. DATE OF REVISION OF THE TEXT
Kora Healthcare
Company Products
| Medicine Name | Active Ingredients |
|---|---|
| Medicine Name Catephen 10% Ointment | Active Ingredients Camellia sinensis (green tea) leaf extract |
| Medicine Name Imunovir 500mg Tablets | Active Ingredients Inosine acedoben dimepranol |
| Medicine Name Magnaspartate 243 mg powder for oral solution | Active Ingredients Magnesium aspartate dihydrate |
When a pharmaceutical company changes any document, a new version is published on medicines.ie. For each version, we show the dates it was published on medicines.ie and the reasons for change.
Updated on 26 June 2017 PIL
Reasons for updating
- Change to section 2 - what you need to know - warnings and precautions
- Change to section 4 - how to report a side effect
Updated on 26 June 2017 PIL
Reasons for updating
- New PIL for new product
Updated on 14 August 2015 PIL
Reasons for updating
- Change to drug interactions
- Addition of information on reporting a side effect.
Updated on 11 March 2015 SPC
Reasons for updating
- Change to section 4.4 - Special warnings and precautions for use
- Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
- Change to section 4.8 - Undesirable effects
Legal category: Product subject to medical prescription which may not be renewed (A)
Free text change information supplied by the pharmaceutical company
In some people acute hypersensitivity reactions (urticarial, angioedema, anaphylaxis) may occur. Treatment with Imunovir should be withdrawn in these cases.
Imunovir contains wheat starch. Suitable for people with coeliac disease. Patients with wheat allergy (different from coeliac disease) should not take this medicine.
In Section 4.5 the following text has been added:
Isoprinosine may be administered after but not concomitantly with immunosuppressive agents, as there may be a pharmacokinetic influence on the desired therapeutic effects.
Concomitant use with AZT increases AZT nucleotide formation through multiple mechanisms involving increased plasma AZT bioavailability and increased intracellular phosphorylation in human blood monocytes.
As a result Imunovir increases the effect of AZT.
Section 4.8 has been reformatted and includes the details for reporting of suspected adverse reactions.
Updated on 11 March 2015 SPC
Reasons for updating
- New SPC for new product
Legal category: Product subject to medical prescription which may not be renewed (A)
Updated on 24 August 2012 PIL
Reasons for updating
- New PIL for medicines.ie
Updated on 3 April 2012 SPC
Reasons for updating
- New SPC for medicines.ie
Legal category: Product subject to medical prescription which may not be renewed (A)